Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2003 3
2004 1
2005 2
2006 4
2007 2
2008 1
2009 1
2010 3
2011 4
2012 2
2013 6
2014 5
2015 5
2016 6
2017 6
2018 5
2019 6
2020 11
2021 8
2022 6
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Adult nodular lymphocyte predominant Hodgkin lymphoma"
Page 1
Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Yasuda H, Yasuda M, Komatsu N. Yasuda H, et al. Cancer Sci. 2021 Jul;112(7):2607-2624. doi: 10.1111/cas.14933. Epub 2021 Jun 11. Cancer Sci. 2021. PMID: 33938097 Free PMC article.
Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. ...
Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. ...
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML. Hill HA, et al. Blood Adv. 2020 Jul 14;4(13):2927-2938. doi: 10.1182/bloodadvances.2019001350. Blood Adv. 2020. PMID: 32598477 Free PMC article.
Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. ...Our data also show a change in mutational status from baseline samples to samples at disease progression and presen …
Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeut …
Acquired ichthyosis: a clinical review.
Haber R, Feghali J, Nadir U, Yi MD, Cahn BA. Haber R, et al. Arch Dermatol Res. 2023 Nov;315(9):2529-2543. doi: 10.1007/s00403-023-02668-5. Epub 2023 Jul 9. Arch Dermatol Res. 2023. PMID: 37422878 Review.
Total number of included patients was 167 patients with a mean age at presentation of 39 years [range 0.5-85] and a sex ratio M:F of 5:2. The most common malignancy associated with AI is Hodgkin's lymphoma. AI occurred before, simultaneously or after the onset of ma …
Total number of included patients was 167 patients with a mean age at presentation of 39 years [range 0.5-85] and a sex ratio M:F of 5:2. Th …
Hodgkin Lymphoma in Adults.
Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N. Bröckelmann PJ, et al. Dtsch Arztebl Int. 2018 Aug 6;115(31-32):535-540. doi: 10.3238/arztebl.2018.0535. Dtsch Arztebl Int. 2018. PMID: 30149835 Free PMC article.
BACKGROUND: Hodgkin lymphoma is the most common neoplasm in young adults, with an incidence of 2 to 3 cases per 100 000 persons per year. ...In advanced stages, two cycles of escalated BEACOPP are administered, and then PET is performed for the guidance of fu …
BACKGROUND: Hodgkin lymphoma is the most common neoplasm in young adults, with an incidence of 2 to 3 cases per 100 000 …
Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
Dada R, Zekri J, Al Saadi R. Dada R, et al. Expert Opin Biol Ther. 2016 Jun;16(6):739-45. doi: 10.1080/14712598.2016.1180362. Epub 2016 May 3. Expert Opin Biol Ther. 2016. PMID: 27096887 Review.
OBJECTIVES: This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV) in patients with relapsed/refractory Hodgkin lymphoma (HL). PATIENTS AND METHODS: A systematic literature search was performed and included studies published from 1(st) Janu …
OBJECTIVES: This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV) in patients with relapsed/refractory Hodgkin …
Adolescents and young adults with non-Hodgkin's lymphoma: slipping between the cracks.
Wolach O, Ram R. Wolach O, et al. Acta Haematol. 2014;132(3-4):279-91. doi: 10.1159/000360212. Epub 2014 Sep 10. Acta Haematol. 2014. PMID: 25228553 Review.
Non-Hodgkin's lymphoma (NHL) comprises approximately 7% of cancer among AYAs, and patient allocation and therapy vary between health systems. In this systematic review we focus on the current biological and clinical knowledge relevant to AYAs with NHL applying these …
Non-Hodgkin's lymphoma (NHL) comprises approximately 7% of cancer among AYAs, and patient allocation and therapy vary between …
Challenges and opportunities in primary CNS lymphoma: A systematic review.
Kerbauy MN, Moraes FY, Lok BH, Ma J, Kerbauy LN, Spratt DE, Santos FP, Perini GF, Berlin A, Chung C, Hamerschlak N, Yahalom J. Kerbauy MN, et al. Radiother Oncol. 2017 Mar;122(3):352-361. doi: 10.1016/j.radonc.2016.12.033. Epub 2017 Jan 16. Radiother Oncol. 2017. PMID: 28104300 Review.
BACKGROUND: Historically, high-dose methotrexate (HD-MTX) plus consolidation chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on Primary Central Nervous System Lymphoma (PCNSL) management. We sought to examine and summarize the data, on clinic …
BACKGROUND: Historically, high-dose methotrexate (HD-MTX) plus consolidation chemotherapy and/or whole brain radiotherapy (WBRT) has been th …
Rituximab in Hodgkin lymphoma: is the target always a hit?
Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA. Saini KS, et al. Cancer Treat Rev. 2011 Aug;37(5):385-90. doi: 10.1016/j.ctrv.2010.11.005. Epub 2010 Dec 22. Cancer Treat Rev. 2011. PMID: 21183282 Review.
In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in a new era of rationally designed targeted agents in cancer therapeutics. It is currently approved for use in non-Hodgkin lymphoma (N …
In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in a new …
Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.
Fama A, Larson MC, Link BK, Habermann TM, Feldman AL, Call TG, Ansell SM, Liebow M, Xiang J, Maurer MJ, Slager SL, Nowakowski GS, Stapleton JT, Cerhan JR. Fama A, et al. Clin Infect Dis. 2020 Aug 22;71(5):1221-1228. doi: 10.1093/cid/ciz940. Clin Infect Dis. 2020. PMID: 31671178 Free PMC article.
METHODS: We conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects mo …
METHODS: We conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association …
Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review.
Wieser I, Wohlmuth C, Nunez CA, Duvic M. Wieser I, et al. Am J Clin Dermatol. 2016 Aug;17(4):319-27. doi: 10.1007/s40257-016-0192-6. Am J Clin Dermatol. 2016. PMID: 27138554 Review.
BACKGROUND: Lymphomatoid papulosis (LyP) is a lymphoproliferative disorder that is rare among adults and even rarer among children. In adults, LyP is associated with an increased risk of secondary lymphomas. OBJECTIVE: The aim of this systematic review was to descri …
BACKGROUND: Lymphomatoid papulosis (LyP) is a lymphoproliferative disorder that is rare among adults and even rarer among children. I …
90 results